FWA
ELVN icon

Freedom Wealth Alliance’s Enliven Therapeutics ELVN Stock Holding History

Freedom Wealth Alliance’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-775
Closed -$12.7K – 175
2022
Q4 		$12.7K Buy
+775
New +$12.4K 0.02% 256

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Freedom Wealth Alliance's ELVN Position: Q1 2023 in Review

Freedom Wealth Alliance sold out of Enliven Therapeutics (ELVN) in Q1 2023, closing a stake of 775 shares — an estimated $12.7K sold.

Freedom Wealth Alliance first reported a position in ELVN in Q4 2022 and held it in 1 quarter. The position peaked at $12.7K in Q4 2022. 45 funds tracked by Wall St. Rank hold ELVN as of Q1 2023.

  • Freedom Wealth Alliance reported no remaining Enliven Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Freedom Wealth Alliance sold 775 Enliven Therapeutics shares in Q1 2023, an estimated $12.7K.
  • Freedom Wealth Alliance first reported a position in Enliven Therapeutics in Q4 2022 and held it in 1 quarter.
  • Freedom Wealth Alliance's Enliven Therapeutics position peaked at $12.7K in Q4 2022.
  • 45 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2023.

Based on Freedom Wealth Alliance's 13F filing for Q1 2023, filed 25 Apr 2023.